When is Sentinel Lymph Node Biopsy Useful in Ductal Carcinoma In Situ? The Experience at a Latin American Cancer Center

Introduction Ductal carcinoma in situ (DCIS) accounts for 15% of breast cancers. Surgery is the main treatment, and the use of sentinel node biopsy (SLNB) is restricted to patients at risk of infiltration, which is estimated to be around 26%. Materials and methods Aimed at evaluating the benefit of...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz Casas, Sandra E, Serrano Muñoz, Wilmar A, Buelvas Gómez, Nelson A, Osorio Ruiz, Ana M, Ángel Aristizábal, Javier, Guzmán Abisaab, Luis H, Garcia Mora, Mauricio, Lehmann Mosquera, Carlos, Cervera-Bonilla, Sergio, Sanchez Pedraza, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
General Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327396/
https://www.ncbi.nlm.nih.gov/pubmed/34354880
http://dx.doi.org/10.7759/cureus.16134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327396/
https://www.ncbi.nlm.nih.gov/pubmed/34354880
http://dx.doi.org/10.7759/cureus.16134

Ejemplares similares